T1	PROC 93 101	tratados
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	CHEM 54 63	nivolumab
#2	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 66 76	ipilimumab
#3	AnnotatorNotes T3	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	DISO 106 110	CPNM
#4	AnnotatorNotes T4	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T5	PROC 174 181	cirugía
#5	AnnotatorNotes T5	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T6	PROC 203 239	Ensayo fase 3, aleatorizado, abierto
T7	CHEM 255 264	nivolumab
#6	AnnotatorNotes T7	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	PROC 269 300	quimiorradioterapia concurrente
T9	CHEM 321 330	nivolumab
#7	AnnotatorNotes T9	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 335 345	ipilimumab
#8	AnnotatorNotes T10	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	CHEM 348 357	nivolumab
#9	AnnotatorNotes T11	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 380 389	nivolumab
#10	AnnotatorNotes T12	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	CHEM 416 426	durvalumab
#11	AnnotatorNotes T13	C4055109; durvalumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	DISO 433 464	cáncer de pulmón no microcítico
#12	AnnotatorNotes T14	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T15	DISO 486 490	CPNM
#13	AnnotatorNotes T15	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T16	DISO 540 556	Cáncer de pulmón
#14	AnnotatorNotes T16	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T17	DISO 582 613	Cáncer de pulmón no microcítico
#15	AnnotatorNotes T17	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T18	DISO 659 663	CPNM
#16	AnnotatorNotes T18	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T19	PROC 498 505	tratado
#17	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	DISO 830 834	CPNM
#18	AnnotatorNotes T20	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T21	PROC 909 920	diagnóstico
#19	AnnotatorNotes T21	C0011900; Diagnosis; Diagnostic Procedure
T22	PROC 925 936	tratamiento
#20	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 942 967	tratamiento anticanceroso
T24	PROC 1003 1023	tratamiento primario
#21	AnnotatorNotes T24	C1708063; First line treatment; Therapeutic or Preventive Procedure
T25	DISO 1029 1039	enfermedad
#22	AnnotatorNotes T25	C0012634; Disease; Disease or Syndrome
T26	PROC 1126 1135	protocolo
#23	AnnotatorNotes T26	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T27	PROC 1298 1307	protocolo
#24	AnnotatorNotes T27	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T28	PROC 1371 1382	Tratamiento
#25	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	CHEM 1397 1417	anticuerpo anti-PD-1
T30	CHEM 1419 1429	anti-PD-L1
T31	CHEM 1431 1441	anti-PD-L2
T32	CHEM 1444 1455	anti-CTLA-4
T33	CHEM 1474 1484	anticuerpo
#26	AnnotatorNotes T33	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T34	CHEM 1487 1584	fármaco dirigido específicamente a la co estimulación de células T o las vías de punto de control
#27	AnnotatorNotes T34	C3192215; Selective T Cell Costimulation Blocker; Pharmacologic Substance (?) | C4684977; Immune Checkpoint Inhibitors; Pharmacologic Substance (?)
T35	ANAT 1544 1553	células T
#28	AnnotatorNotes T35	C0039194; T-Lymphocyte; Cell
T36	DISO 1587 1596	Infección
#29	AnnotatorNotes T36	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T37	PROC 1617 1634	terapia sistémica
#30	AnnotatorNotes T37	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
T38	PROC 1673 1687	aleatorización
#31	AnnotatorNotes T38	C0034656; Randomization; Research Activity
T39	DISO 1690 1708	Enfermedad maligna
T40	DISO 1764 1772	cánceres
#32	AnnotatorNotes T40	C0006826; Malignant Neoplasms; Neoplastic Process
T41	DISO 1854 1875	enfermedad autoinmune
#33	AnnotatorNotes T41	C0004364; Autoimmune Diseases; Disease or Syndrome
T42	DISO 1912 1920	afección
#34	AnnotatorNotes T42	C0221423; Illness (finding); Sign or Symptom
T43	PROC 1934 1955	tratamiento sistémico
T44	CHEM 1960 1976	corticosteroides
#35	AnnotatorNotes T44	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T45	CHEM 1989 1999	prednisona
#36	AnnotatorNotes T45	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T46	CHEM 2031 2060	medicamentos inmunosupresores
T47	PROC 2105 2119	aleatorización
#37	AnnotatorNotes T47	C0034656; Randomization; Research Activity
T48	ANAT 2159 2166	tejidos
#38	AnnotatorNotes T48	C0040300; Body tissue; Tissue | C1284837; Entire body tissue; Tissue
T49	CHEM 2200 2216	inmunosupresores
#39	AnnotatorNotes T49	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T50	PROC 2256 2277	Radioterapia torácica
T51	ANAT 2269 2277	torácica
#40	AnnotatorNotes T51	C0817096; Chest; Body Location or Region | C1269614; Entire thorax; Body Part, Organ, or Organ Component
T52	PROC 2352 2361	protocolo
#41	AnnotatorNotes T52	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T53	ANAT 443 449	pulmón
#42	AnnotatorNotes T53	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T54	ANAT 453 464	microcítico
#43	AnnotatorNotes T54	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T55	ANAT 550 556	pulmón
#44	AnnotatorNotes T55	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T56	ANAT 592 598	pulmón
#45	AnnotatorNotes T56	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T57	ANAT 602 613	microcítico
#46	AnnotatorNotes T57	C1514085; Neoplastic Small Cell; Cell | C1518241; Malignant Small Cell; Cell
T58	PROC 649 656	tratado
#47	AnnotatorNotes T58	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T59	DISO 1173 1214	condición médica, emocional, psiquiátrica
T60	PROC 2135 2166	trasplante de órganos o tejidos
T61	ANAT 2149 2156	órganos
#48	AnnotatorNotes T61	C0178784; Organ; Body Part, Organ, or Organ Component | C1280836; Entire body organ; Body Part, Organ, or Organ Component
T62	DISO 2240 2255	pérdida de oído
T64	Date 12 16	2019
T65	LIVB 80 89	pacientes
#49	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	Neg_cue 90 92	no
T68	Neg_cue 139 141	no
T69	Neg_cue 450 452	no
T70	Neg_cue 495 497	no
T71	Neg_cue 599 601	no
T72	Neg_cue 646 648	no
T73	Neg_cue 938 941	sin
T76	LIVB 1247 1259	investigador
#50	AnnotatorNotes T76	C0035173; Research Personnel; Professional or Occupational Group
T78	LIVB 1275 1283	paciente
#51	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T80	Duration 1645 1656	los 14 días
T81	Duration 1726 1747	los 3 años anteriores
T82	Neg_cue 1749 1756	excepto
T83	Spec_cue 1895 1905	sospechada
T84	Dose 1978 1985	> 10 mg
T85	Frequency 2000 2007	diarios
T86	Duration 2071 2082	los 14 días
T88	PHYS 2251 2255	oído
#52	AnnotatorNotes T88	C0018767; Hearing; Physiologic Function
T74	PHYS 1525 1553	co estimulación de células T
#53	AnnotatorNotes T74	C1622572; T cell costimulation; Cell Function
T63	LIVB 1832 1845	participantes
#54	AnnotatorNotes T63	C4554048; Study Participant; Population Group
T67	PROC 835 851	histológicamente
#55	AnnotatorNotes T67	C0344441; Histology Procedure; Laboratory Procedure
T75	PHYS 1191 1200	emocional
#56	AnnotatorNotes T75	C0013987; Emotions; Mental Process
A1	Assertion T1 Negated
A2	Assertion T5 Negated
A3	Assertion T54 Negated
A4	Assertion T19 Negated
A5	Assertion T57 Negated
A6	Assertion T58 Negated
A7	Assertion T23 Negated
A8	Assertion T40 Negated
A9	Assertion T41 Speculated
A10	Status T19 History_of
A11	Status T58 History_of
A12	Status T23 History_of
A13	Status T28 History_of
A14	Status T29 History_of
A15	Status T30 History_of
A16	Status T31 History_of
A17	Status T32 History_of
A18	Status T33 History_of
A19	Status T34 History_of
A20	Status T50 History_of
A21	Status T60 History_of
A22	Status T41 History_of
A23	Status T39 History_of
A24	Status T40 History_of
#57	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C1709323; Open Label Study; Research Activity 
#58	AnnotatorNotes T8	C3178775; Concurrent Chemoradiotherapy; Therapeutic or Preventive Procedure 
#59	AnnotatorNotes T23	C0920425; cancer treatment; Therapeutic or Preventive Procedure
#60	AnnotatorNotes T59	C4745084; Medical Condition; Finding + C3843038; Emotional or mental condition; Finding
#61	AnnotatorNotes T32	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
#62	AnnotatorNotes T46	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
#63	AnnotatorNotes T60	C0080232; Tissue Transplantation; Therapeutic or Preventive Procedure + C0029216; Organ Transplantation; Therapeutic or Preventive Procedure
#64	AnnotatorNotes T62	C1384666; hearing impairment; Disease or Syndrome 
#65	AnnotatorNotes T29	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#66	AnnotatorNotes T30	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T77	Neg_cue 1261 1267	impida
T79	Observation 1284 1307	se adhiera al protocolo
A25	Assertion T79 Negated
R1	Negation Arg1:T77 Arg2:T79	
T87	Spec_cue 1063 1070	Podrían
T89	Quantifier_or_Qualifier 1081 1086	otros
A26	Assertion T89 Speculated
T90	CONC 1087 1109	criterios de inclusión
A27	Assertion T90 Speculated
T91	Spec_cue 2288 2295	Podrían
T92	Quantifier_or_Qualifier 2306 2311	otros
A28	Assertion T92 Speculated
T93	CONC 2312 2334	criterios de exclusión
A29	Assertion T93 Speculated
#67	AnnotatorNotes T93	C0680251; Exclusion Criteria; Functional Concept
T94	Quantifier_or_Qualifier 1773 1792	localmente curables
A30	Assertion T94 Negated
R2	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T94	
T95	Observation 1797 1827	aparentemente han sido curados
A31	Assertion T95 Negated
R3	Negation Arg1:T82 Arg2:T40	
R4	Negation Arg1:T82 Arg2:T94	
R5	Negation Arg1:T82 Arg2:T95	
R6	Speculation Arg1:T83 Arg2:T41	
R7	Speculation Arg1:T91 Arg2:T92	
R8	Speculation Arg1:T91 Arg2:T93	
R9	Has_Quantifier_or_Qualifier Arg1:T93 Arg2:T92	
T96	CONC 873 890	clasificación TNM
#68	AnnotatorNotes T96	C1515169; TNM Staging System; Classification
T97	Result_or_Value 736 738	≤1
T98	CONC 694 728	Eastern Cooperative Oncology Group
#69	AnnotatorNotes T98	C1520224; ECOG performance status; Intellectual Product
R10	Has_Result_or_Value Arg1:T98 Arg2:T97	
T99	CONC 730 734	ECOG
#70	AnnotatorNotes T99	C1520224; ECOG performance status; Intellectual Product
R11	Has_Result_or_Value Arg1:T99 Arg2:T97	
R12	Negation Arg1:T71 Arg2:T57	
R13	Location_of Arg1:T56 Arg2:T17	
R14	Location_of Arg1:T55 Arg2:T16	
T100	Quantifier_or_Qualifier 614 633	localmente avanzado
R15	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T100	
R16	Negation Arg1:T72 Arg2:T58	
R17	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T100	
R18	Experiences Arg1:T65 Arg2:T2	
R19	Experiences Arg1:T65 Arg2:T3	
R20	Experiences Arg1:T65 Arg2:T1	
R21	Negation Arg1:T66 Arg2:T1	
R22	Experiences Arg1:T65 Arg2:T4	
T101	Quantifier_or_Qualifier 114 123	estadio 3
R23	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T101	
R24	Negation Arg1:T68 Arg2:T5	
R25	Combined_with Arg1:T7 Arg2:T8	
R26	Combined_with Arg1:T9 Arg2:T10	
R27	Before Arg1:T7 Arg2:T9	
T102	PROC 362 366	QRTC
T103	PROC 302 306	QRTC
#71	AnnotatorNotes T103	C3178775; Concurrent Chemoradiotherapy; Therapeutic or Preventive Procedure
T104	PROC 399 403	QRTC
#72	AnnotatorNotes T104	C3178775; Concurrent Chemoradiotherapy; Therapeutic or Preventive Procedure
#73	AnnotatorNotes T102	C3178775; Concurrent Chemoradiotherapy; Therapeutic or Preventive Procedure
R29	Combined_with Arg1:T7 Arg2:T103	
R30	Before Arg1:T11 Arg2:T12	
R31	Combined_with Arg1:T11 Arg2:T102	
R32	Before Arg1:T104 Arg2:T13	
R33	Location_of Arg1:T53 Arg2:T14	
R34	Negation Arg1:T69 Arg2:T54	
R35	Location_of Arg1:T54 Arg2:T14	
T105	Quantifier_or_Qualifier 465 484	localmente avanzado
R36	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T105	
R37	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T105	
R38	Negation Arg1:T70 Arg2:T19	
T106	Quantifier_or_Qualifier 739 766	Estadio localmente avanzado
T107	Quantifier_or_Qualifier 903 920	Nuevo diagnóstico
#74	AnnotatorNotes T107	C1518321; Newly Diagnosed; Qualitative Concept
R39	Negation Arg1:T73 Arg2:T23	
T108	Quantifier_or_Qualifier 975 980	local
#75	AnnotatorNotes T108	C0205276; Local; Spatial Concept
R40	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T108	
A32	Status T108 History_of
T109	Quantifier_or_Qualifier 983 992	sistémico
#76	AnnotatorNotes T109	C0205373; Systemic; Functional Concept
R41	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T109	
A33	Status T109 History_of
A34	Assertion T108 Negated
A35	Assertion T109 Negated
R42	Negation Arg1:T73 Arg2:T108	
R43	Negation Arg1:T73 Arg2:T109	
T110	Quantifier_or_Qualifier 1040 1059	localmente avanzada
R44	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T110	
R45	Speculation Arg1:T87 Arg2:T89	
R46	Has_Quantifier_or_Qualifier Arg1:T90 Arg2:T89	
R47	Speculation Arg1:T87 Arg2:T90	
R49	Before Arg1:T59 Arg2:T79	
R50	Experiences Arg1:T78 Arg2:T59	
T111	Observation 1321 1327	riesgo
R52	Experiences Arg1:T78 Arg2:T111	
T113	Observation 1342 1368	participación en el ensayo
#78	AnnotatorNotes T113	C1278516; Patient participation status; Finding (?)
R53	Overlap Arg1:T111 Arg2:T113	
R54	Before Arg1:T59 Arg2:T113	
R55	Used_for Arg1:T29 Arg2:T28	
R56	Used_for Arg1:T30 Arg2:T28	
R57	Used_for Arg1:T31 Arg2:T28	
R58	Used_for Arg1:T32 Arg2:T28	
R59	Used_for Arg1:T33 Arg2:T28	
R60	Used_for Arg1:T34 Arg2:T28	
R61	Location_of Arg1:T35 Arg2:T74	
R62	Overlap Arg1:T37 Arg2:T80	
R63	Before Arg1:T37 Arg2:T38	
T114	Quantifier_or_Qualifier 1597 1603	activa
#79	AnnotatorNotes T114	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R64	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T114	
T115	Quantifier_or_Qualifier 1716 1722	activa
#80	AnnotatorNotes T115	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R65	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T115	
T116	Quantifier_or_Qualifier 1876 1882	activa
#81	AnnotatorNotes T116	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R66	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T116	
#82	AnnotatorNotes T39	C0442867; malignant disease; Disease or Syndrome
R67	Overlap Arg1:T39 Arg2:T81	
R68	Location_of Arg1:T51 Arg2:T50	
#83	AnnotatorNotes T50	C4038705; Radiotherapy to thorax; Health Care Activity
R69	Location_of Arg1:T61 Arg2:T60	
R70	Location_of Arg1:T48 Arg2:T60	
T117	Quantifier_or_Qualifier 2187 2196	sistémico
#84	AnnotatorNotes T117	C0205373; Systemic; Functional Concept
R71	Has_Quantifier_or_Qualifier Arg1:T49 Arg2:T117	
R73	Has_Dose_or_Strength Arg1:T45 Arg2:T84	
R74	Has_Frequency Arg1:T45 Arg2:T85	
T118	CONC 1989 1999;2010 2021	prednisona equivalente
R75	Experiences Arg1:T63 Arg2:T41	
R76	Experiences Arg1:T63 Arg2:T42	
#85	AnnotatorNotes T43	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
R77	Experiences Arg1:T63 Arg2:T43	
R78	Used_for Arg1:T44 Arg2:T43	
R79	Used_for Arg1:T45 Arg2:T43	
R80	Used_for Arg1:T46 Arg2:T43	
R81	Overlap Arg1:T46 Arg2:T86	
R82	Before Arg1:T47 Arg2:T46	
R83	Before Arg1:T47 Arg2:T45	
R84	Before Arg1:T47 Arg2:T44	
R85	Before Arg1:T47 Arg2:T43	
R86	Overlap Arg1:T45 Arg2:T86	
R87	Overlap Arg1:T44 Arg2:T86	
T119	Observation 767 771	IIIA
T120	Observation 773 777	IIIB
T121	Observation 781 785	IIIC
T122	Observation 787 799	T1-2 N2-3 M0
#86	AnnotatorNotes T122	C0475372; Tumor stage T1; Finding | C0475373; Tumor stage T2; Finding + C0441960; N2 category (finding); Finding | C0441961; N3 category (finding); Finding + C0445034; M0 Stage Finding; Finding
T124	Observation 815 825	T4 N0-3 M0
#88	AnnotatorNotes T124	C0475751; Tumor stage T4; Finding + C0441959; Node stage N0; Finding | C0441962; Node stage N1; Finding | C0441960; N2 category (finding); Finding | C0441961; N3 category (finding); Finding + C0445034; M0 Stage Finding; Finding
R88	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T119	
R89	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T120	
R90	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T121	
T125	Observation 801 811	T3 N1-3 M0
#89	AnnotatorNotes T125	C0475374; Tumor stage T3; Finding + C0441962; Node stage N1; Finding | C0441960; N2 category (finding); Finding | C0441961; N3 category (finding); Finding + C0445034; M0 Stage Finding; Finding
R91	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T122	
R92	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T125	
R93	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T106	
R94	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T124	
#87	AnnotatorNotes T111	C0559571; At risk - finding; Finding
R48	Experiences Arg1:T65 Arg2:T5	
T123	Quantifier_or_Qualifier 147 155	previsto
#90	AnnotatorNotes T123	C1301732; Planned; Functional Concept
A37	Assertion T123 Negated
R95	Negation Arg1:T68 Arg2:T123	
#91	AnnotatorNotes T89	C0205394; Other; Qualitative Concept
#92	AnnotatorNotes T90	C1512693; Inclusion Criteria; Qualitative Concept
R28	Overlap Arg1:T79 Arg2:T27	
#77	AnnotatorNotes T92	C0205394; Other; Qualitative Concept
#93	AnnotatorNotes T119	C3250646; malignant neoplasm stage IIIA; Finding
#94	AnnotatorNotes T120	C3250647; malignant neoplasm stage IIIB; Finding
#95	AnnotatorNotes T121	C3250648; malignant neoplasm stage IIIC; Finding
A36	Experiencer T78 Patient
A38	Experiencer T76 Other
A39	Experiencer T65 Patient
A40	Status T5 Future
A41	Experiencer T63 Patient
